Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00004142

Trial Description

start of 1:1-Block title

Title

A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

READY

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this study is to determine whether survival can be prolonged in patients with
castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

[---]*

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004142
  •   2012/10/18
  •   2008/08/29
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2008-000701-11 
  •   NCT00744497  (ClinicalTrials.gov)
  •   CA180-227  (Bristol-Myers Squibb)
  •   2008-000701-11 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Prostatic Neoplasms
  •   C61 -  Malignant neoplasm of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Placebo
  •   Drug: Dasatinib
  •   Drug: Docetaxel
  •   Drug: Prednisone
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Placebo, Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Overall Survival: Time From Randomization to Date of Death; time frame: From randomization to death or date of last contact (maximum reached: 45 months); Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST); time frame: At baseline and every 12 weeks thereafter to end of treatment, at end of treatment, and at follow-up (within 42 days of end of dosing); Objective tumor response rate=the percentage of randomized participants with a best tumor response of partial (PR) or complete response (CR), within 42 days of end of dosing, divided by total number of patients who were evaluable (with at least 1 target lesion at baseline). By RECIST: CR=disappearance of clinical and radiologic evidence of target and nontarget lesions confirmed by another evaluation at least 6 weeks later. PR=a >30% or greater decrease in the sum of longest diameter (LD) of target lesions in reference to the baseline sum LD confirmed by another evaluation at least 6 weeks later. Stable disease=neither sufficient increase to qualify for PD nor shrinkage to qualify for PR, and at least 8 weeks since start of study therapy. Progressive disease=a 20% or greater increase in sum of LD of all target lesions, taking as reference the smallest sum of LD at or following baseline, or unequivocal progression on existing nontarget lesions, or new lesions are present.
- Time to First Skeletal-related Event (SRE); time frame: From day of randomization to date of first SRE or to last SRE assessment, if subsequent cancer therapy begun or no SRE (maximum reached: 42 months); Time to first SRE is defined as the time in months from the date of randomization to the date of first SRE (unless SRE occurred while the patient was undergoing subsequent cancer therapy). Participants with a first SRE while on subsequent cancer therapy, those who died without a reported SRE, and those who did not have an SRE were censored on the date of their last SRE assessment prior to start of subsequent cancer therapy, if any. Participants who had no SRE assessments were censored on the day they were randomized.
- Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline; time frame: At baseline, prior to each docetaxel infusion (every 3 weeks) to end of treatment, at end of treatment, and at follow-up (within 14 days of end of dosing); The percentage of participants who had an on-study uNTx value confirmed (at least 3 weeks later) within normal limits (or ≥3 and <60 nmol/mmol creatinine, if normal limits were missing) or an on-study uNTx level reduction from baseline of ≥35%, even when on-study uNTx value remained abnormal.
- Progression-free Survival (PFS); time frame: From day of randomization to disease progression or death (or to last clinical assessment, if subsequent cancer therapy started or no progression or death) (maximum reached: approximately 43 months); PFS is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Those who progressed or died while on subsequent cancer therapy and those who did not die or progress were censored at their last radiologic bone scan/imaging, skeletal related-event, or tumor assessment or at measurement of prostate specific antigen levels, whichever occurred last prior to start of subsequent cancer therapy ,if any. Participants with no assessments were censored on the day of randomization.
- Time to Prostate Specific Antigen (PSA) Progression; time frame: From randomization to date of first PSA measurement leading to confirmed PSA progression (or to last bone scan assessment, if no progression or if cancer therapy started) (maximum reached: 30 months); PSA progression is defined as the time from randomization to the date of the first PSA level measurement that led to confirmed PSA progression, for participants who had not started subsequent cancer therapy. For participants who did not progress or who progressed on cancer therapy, PSA progression is defined as the time from randomization to the date of the last PSA level measurement before the start of cancer therapy, if any. Participants who had no on-study PSA level measurements were censored on the day they were randomized.
- Percentage of Participants With a Reduction in Pain Intensity From Baseline; time frame: At baseline, prior to each docetaxel infusion (every 3 weeks), at end of treatment, and at follow-up (within 14 days of end of dosing); The percentage of participants with a reduction in pain intensity from baseline was defined as the number of participants who achieved a 30% or more decrease in pain intensity from baseline for at least 2 consecutive pain assessments (at least 14 days apart) within 14 days of end of dosing divided by the number of randomized participants who had a baseline pain intensity of at least 2. Pain intensity was assessed based on question 3 of the brief pain inventory questionnaire.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Argentina
  •   Australia
  •   Brazil
  •   Canada
  •   Czech Republic
  •   Finland
  •   France
  •   Germany
  •   Greece
  •   Hungary
  •   India
  •   Ireland
  •   Italy
  •   Korea, Republic of
  •   Mexico
  •   Norway
  •   Peru
  •   Poland
  •   Romania
  •   Russian Federation
  •   South Africa
  •   Spain
  •   Sweden
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2008/10/31
  •   1500
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- History of histologically diagnosed prostate cancer

- Evidence of metastatic disease by any 1 of the following: computed tomography scan,
magnetic resonance imaging, bone scan, or skeletal survey

- Evidence of progression, as defined by 1 of the following: rising prostate specific
antigen levels at least 1 week apart with the final value being >=2 ng/mL;
progression of measurable nodal or visceral disease, with nodal lesions >=20 mm and
visceral lesions measurable per response evaluation criteria for solid tumors
(Response Evaluation in Solid Tumors, version 1); 2 or more lesions appearing on bone
scan compared with previous scan; or local recurrence in the prostate or prostate bed

- Maintaining castrate status: Participants who have not undergone surgical orchiectomy
should have received and continue on medical therapies, such as gonadotropin
releasing hormone analogs, to maintain castrate levels of serum testosterone <=50
ng/dL

- Eastern Cooperative Oncology Group Performance Status of 0 to 2

- At least 4 weeks since an investigational agent prior to starting study therapy

- At least 8 weeks since radioisotope therapy prior to starting study therapy

- Recovery from any local therapy including surgery or radiation/radiotherapy for a
minimum of 7 days prior to starting study therapy

- Required initial laboratory values: white blood cell count >=3,000/mm^3; absolute
neutrophil count >=1,500/mm^3; platelet count >=100,000/mm^3; creatinine level
<=1.5*upper limit of normal (ULN); bilirubin <=ULN; aspartate aminotransferase
<=2.5*ULN; alanine aminotransferase <=2.5*ULN.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Symptomatic brain metastases or leptomeningeal metastases

- Clinically significant cardiovascular disease, including myocardial infarction;
ventricular tachyarrhythmia within 6 months; prolonged QTc >450 msec; ejection
fraction <40%; or major conduction abnormality, unless a cardiac pacemaker is present

- Pleural or pericardial effusion of any Common Terminology Criteria (CTC) grade

- Peripheral neuropathy CTC Grade >=2

- Currently active second malignancy other than nonmelanoma skin cancers. Participants
are not considered to have a currently active malignancy if they have completed
therapy and are now considered (by their physician) to be at less than 30% risk for
relapse

- Uncontrolled intercurrent illness including ongoing or active infection, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- HIV infection-positive patients receiving combination antiretroviral therapy

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to the investigational agents

- Receipt of any other investigational agents for the treatment of prostate cancer

- Prior cytotoxic chemotherapy in the metastatic setting, with the exception of
estramustine

- Patients may continue on a daily multivitamin but must discontinue all other herbal,
alternative, and food supplements before enrollment

- Ketoconazole must be discontinued 4 weeks prior to starting study therapy

- Antiandrogens must be discontinued prior to starting study therapy. Patients with a
history of response to an antiandrogen and subsequent progression while on that
antiandrogen should be assessed for antiandrogen withdrawal response for 4 weeks.
Observation for antiandrogen withdrawal response is not necessary for those who have
never responded to antiandrogens

- Bisphosphonates must not be initiated within 28 days prior to starting study therapy

- QT prolonging agents strongly associated with torsade de pointes.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Bristol-Myers Squibb
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Bristol-Myers Squibb
    • Bristol-Myers Squibb 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Bristol-Myers Squibb
    • Bristol-Myers Squibb 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2015/07/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   6
  •   2016/01/14


* This entry means the parameter is not applicable or has not been set.